Physician profile
Jin Kong
NPI 1376793208
$2,596.52
in general payments reported to CMS, 2019-2025
12 companies · $242 in 2025
The $242 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $563 · 2020: $113 · 2021: $515 · 2022: $320 · 2023: $262 · 2024: $581 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,085.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $640.04 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Welch Allyn | $380.00 | 2021 | |
| Abbvie INC. | $314.08 | 2021-2023 | |
| Supernus Pharmaceuticals, INC. | $312.42 | 2023-2025 | Qelbree, Qelbree |
| Allergan, INC. | $209.27 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $203.09 | 2019 | |
| Alkermes, INC. | $119.91 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $115.76 | 2024 | Uzedy |
| Sun Pharmaceutical Industries INC. | $108.29 | 2024 | |
| Neurocrine Biosciences, INC. | $89.37 | 2022 | |
| Sunovion Pharmaceuticals INC. | $80.23 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $24.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jin Kong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.